$EVOK
Evoke Pharma Inc

2018 Q1 Form 10-Q Financial Statement

#000156459018013308 Filed on May 14, 2018

View on sec.gov

Income Statement

Concept 2018 Q1 2017 Q4 2017 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.030M $1.030M $1.210M
YoY Change -14.88% 25.61% 6.14%
% of Gross Profit
Research & Development $1.385M $1.632M $770.7K
YoY Change 79.76% 8.62% -61.75%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $2.418M $1.632M $1.980M
YoY Change 22.09% 8.62% -37.19%
Operating Profit -$2.418M -$1.980M
YoY Change 22.09% -37.19%
Interest Expense $1.433K $0.00 $964.00
YoY Change 48.65% -101.33%
% of Operating Profit
Other Income/Expense, Net $434.8K $2.350M -$3.072M
YoY Change -114.16% 193.75% 4132.27%
Pretax Income -$1.980M -$310.0K -$5.050M
YoY Change -60.79% -79.74% 56.35%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$1.983M -$308.4K -$5.052M
YoY Change -60.75% -79.81% 56.63%
Net Earnings / Revenue
Basic Earnings Per Share -$0.02 -$0.37
Diluted Earnings Per Share -$128.3K -$0.07 -$0.37
COMMON SHARES
Basic Shares Outstanding 15.37M 13.53M
Diluted Shares Outstanding 15.50M 13.53M

Balance Sheet

Concept 2018 Q1 2017 Q4 2017 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.410M $7.680M $14.66M
YoY Change -63.1% -14.76% 140.33%
Cash & Equivalents $5.410M $7.679M $14.65M
Short-Term Investments
Other Short-Term Assets $180.0K $250.0K $170.0K
YoY Change 5.88% 3026.17% -77.92%
Inventory
Prepaid Expenses $251.0K
Receivables
Other Receivables
Total Short-Term Assets $5.580M $7.930M $14.83M
YoY Change -62.37% -14.57% 115.87%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $11.55K $11.55K
YoY Change -100.0% 15.51%
Total Long-Term Assets $0.00 $11.55K $10.00K
YoY Change -100.0% 59.96%
TOTAL ASSETS
Total Short-Term Assets $5.580M $7.930M $14.83M
Total Long-Term Assets $0.00 $11.55K $10.00K
Total Assets $5.580M $7.942M $14.84M
YoY Change -62.4% -14.51% 116.01%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $550.0K $1.050M $550.0K
YoY Change 0.0% 118.75% -55.65%
Accrued Expenses $650.0K $1.030M $590.0K
YoY Change 10.17% 10.75% 22.92%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.196M $2.070M $1.140M
YoY Change 4.88% 46.81% -53.09%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $0.00 $3.700M $5.770M
YoY Change -100.0% -9.76%
Total Long-Term Liabilities $0.00 $3.700M $5.770M
YoY Change -100.0% -9.76% 56.79%
TOTAL LIABILITIES
Total Short-Term Liabilities $1.196M $2.070M $1.140M
Total Long-Term Liabilities $0.00 $3.700M $5.770M
Total Liabilities $1.196M $5.776M $6.900M
YoY Change -82.67% 4.83% 12.75%
SHAREHOLDERS EQUITY
Retained Earnings -$73.02M -$71.04M
YoY Change 20.8%
Common Stock $77.41M $73.20M
YoY Change 16.95%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $4.389M $2.166M $7.930M
YoY Change
Total Liabilities & Shareholders Equity $5.585M $7.942M $14.84M
YoY Change -62.37% -14.55% 116.01%

Cashflow Statement

Concept 2018 Q1 2017 Q4 2017 Q1
OPERATING ACTIVITIES
Net Income -$1.983M -$308.4K -$5.052M
YoY Change -60.75% -79.81% 56.63%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$2.818M -$2.740M -$1.690M
YoY Change 66.74% 100.0% -37.17%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $544.6K $7.335M
YoY Change -92.57% 7328.04%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 544.6K 0.000 7.330M
YoY Change -92.57% -100.0% 7230.0%
NET CHANGE
Cash From Operating Activities -2.818M -2.740M -1.690M
Cash From Investing Activities
Cash From Financing Activities 544.6K 0.000 7.330M
Net Change In Cash -2.273M -2.740M 5.640M
YoY Change -140.31% 98.55% -317.76%
FREE CASH FLOW
Cash From Operating Activities -$2.818M -$2.740M -$1.690M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1032245
CY2018Q1 us-gaap Operating Expenses
OperatingExpenses
2417611
CY2018Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-2417611
CY2018Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
1433
CY2018Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-433392
CY2018Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-83682
CY2017Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-104184
CY2018Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-879245
CY2017Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-275862
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-2817966
CY2017Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-1686812
CY2018Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
544643
CY2017Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
7334739
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
544643
CY2017Q1 us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
7334739
CY2018Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-2273323
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7941864
CY2018Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2018Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-73021441
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-71038655
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
4389266
CY2018Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15682480
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
73202863
CY2018Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1195593
CY2018Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
77409139
CY2018Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15682480
CY2017Q4 evok Warrant Liability
WarrantLiability
3701277
CY2018Q1 us-gaap Liabilities
Liabilities
1195593
CY2017Q4 us-gaap Liabilities
Liabilities
5776115
CY2018Q1 us-gaap Common Stock Value
CommonStockValue
1568
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
2165749
CY2018Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
5584859
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
15413610
CY2018Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1385366
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
1541
CY2017Q1 us-gaap Share Based Compensation
ShareBasedCompensation
464158
CY2017Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
13528311
CY2017Q1 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
770686
CY2017Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1209570
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-1982786
CY2017Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-3071783
CY2017Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15427037
CY2017Q1 us-gaap Net Income Loss
NetIncomeLoss
-5052039
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
15413610
CY2017Q1 us-gaap Operating Expenses
OperatingExpenses
1980256
CY2017Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1980256
CY2017Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
964
CY2017Q1 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
3072747
CY2018Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
434825
CY2018Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.13
CY2018Q1 us-gaap Share Based Compensation
ShareBasedCompensation
393775
CY2017Q1 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5647927
CY2016Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9007071
CY2017Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14654998
CY2017Q1 evok Reclassification Of Warrant Liability To Equity Due To Exercise Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToExerciseOfWarrants
1399091
CY2018Q1 evok Reclassification Of Warrant Liability To Equity Due To Amendment Of Warrants
ReclassificationOfWarrantLiabilityToEquityDueToAmendmentOfWarrants
3267885
CY2018Q1 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company relies on a contract research organization (&#8220;CRO&#8221;) to manage the preparation and submission of the planned NDA.&nbsp;&nbsp;If this CRO is unable to continue the management of the NDA preparation, the delays could adversely affect the timing of the filing of the Company&#8217;s NDA with FDA.</p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, the Company relies on third-party manufacturers for the production of its drug candidate. If the third-party manufacturers are unable to continue manufacturing the Company&#8217;s drug candidate, or if the Company loses one of its sole source suppliers used in its manufacturing processes, the Company may not be able to meet any development needs or commercial supply demand for Gimoti, if approved by FDA, and the development and/or commercialization of Gimoti could be materially and adversely affected.</p></div>
CY2018Q1 us-gaap Fair Value Assets Level1 To Level2 Transfers Amount
FairValueAssetsLevel1ToLevel2TransfersAmount
0
CY2018Q1 us-gaap Fair Value Assets Level2 To Level1 Transfers Amount
FairValueAssetsLevel2ToLevel1TransfersAmount
0
CY2018Q1 us-gaap Fair Value Liabilities Level1 To Level2 Transfers Amount
FairValueLiabilitiesLevel1ToLevel2TransfersAmount
0
CY2018Q1 us-gaap Fair Value Liabilities Level2 To Level1 Transfers Amount
FairValueLiabilitiesLevel2ToLevel1TransfersAmount
0
CY2018Q1 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2018Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2017Q1 us-gaap Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation
WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation
45000
CY2018Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5661087
CY2017Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4773370
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2017Q1 us-gaap Accrued Payroll Taxes Current
AccruedPayrollTaxesCurrent
80000
CY2017Q1 us-gaap Stock Issued During Period Shares Employee Stock Purchase Plans
StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
50244
CY2018Q2 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
6286425
CY2018Q2 evok Share Based Compensation Arrangement By Share Based Payment Award Expiration Month And Year
ShareBasedCompensationArrangementByShareBasedPaymentAwardExpirationMonthAndYear
2028-02
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2500000
CY2018Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y5M19D
CY2018Q1 us-gaap Fair Value Assumptions Risk Free Interest Rate
FairValueAssumptionsRiskFreeInterestRate
0.0209
CY2018Q1 us-gaap Fair Value Assumptions Expected Volatility Rate
FairValueAssumptionsExpectedVolatilityRate
1.0039
CY2018Q1 us-gaap Fair Value Assumptions Expected Term
FairValueAssumptionsExpectedTerm
P4Y29D
CY2018Q1 us-gaap Fair Value Assumptions Expected Dividend Rate
FairValueAssumptionsExpectedDividendRate
0.000

Files In Submission

Name View Source Status
0001564590-18-013308-index-headers.html Edgar Link pending
0001564590-18-013308-index.html Edgar Link pending
0001564590-18-013308.txt Edgar Link pending
0001564590-18-013308-xbrl.zip Edgar Link pending
evok-10q_20180331.htm Edgar Link pending
evok-20180331.xml Edgar Link completed
evok-20180331.xsd Edgar Link pending
evok-20180331_cal.xml Edgar Link unprocessable
evok-20180331_def.xml Edgar Link unprocessable
evok-20180331_lab.xml Edgar Link unprocessable
evok-20180331_pre.xml Edgar Link unprocessable
evok-ex101_336.htm Edgar Link pending
evok-ex311_6.htm Edgar Link pending
evok-ex312_9.htm Edgar Link pending
evok-ex321_8.htm Edgar Link pending
evok-ex322_7.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending